檢視口服避孕藥與婦癌的關係

Oral Contraceptives and Risk of Gynecologic Cancers

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 沈仁達(Jen-a Shen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2012年1期 (2012/01) Pp. 116-125

https://doi.org/10.7010/JGO.201201.0116

摘要

自1960年始，荷爾蒙避孕藥已成為已開發中國家婦女常用的避孕方法，因而發現生育因子和荷爾蒙常會改變某些癌症的發生率。據文獻統計，感染人類乳突病毒和使用口服避孕藥的婦女，會略增子宮頸癌的發生率。但口服避孕藥之使用者，又會減少子宮內膜癌罹患與卵巢癌的發生率，使用藥物時間越長，效果越佳，即使在有BRCA1和2突變之婦女，仍有減少卵巢癌發生率的效果。使用口服避孕藥可望成為防止婦癌發生的一種方法。

關鍵字

口服避孕藥 ； 子宮頸癌 ； 子宮內膜癌 ； 卵巢癌

並列摘要

Hormoral contraceptives has been introduced in the early 1960s and they have become a dominant form of female contraception in most developed countries. It is well documented that reproductive factors and hormone significantly modulate risk of certain cancers. With regard to cervical cancer, oral contraceptives use has been found to be associated with increased risk in human papilloma virus positive women. In literature review, the risk of endometrial cancer is reduced by about 50% in ever users, a benefit which is greater with increasing duration of use. Combined oral contraceptives have a signicant protective effect on the risk of ovarian cancer, and the protection increases with duration of use. The significant risk reduction has been confirmed for BRCA1 and 2 mutation carriers. Importantly, the use of oral contraceptives might become a new strategy for primary protection from gynecological cancers.

並列關鍵字

oral contraceptives ； cervical cancer ； endometrial cancer ； ovarian cancer